Ozoralizumab
Jump to navigation
Jump to search
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Clinical data | |
Trade names | Nanozora |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C1682H2608N472O538S12 |
Molar mass | 38434.85 g·mol−1 |
(what is this?) (verify) |
Ozoralizumab (trade name Nanozora) is a trivalent anti-tumour necrosis factor alpha (TNFα) nanobody designed for the treatment of inflammatory diseases.[1]
Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to Eddingpharm. In 2022, ozoralizumab was approved in Japan for the treatment of rheumatoid arthritis.[2]
References
- ^ Kratz F, Elsadek B (July 2012). "Clinical impact of serum proteins on drug delivery". J Control Release. 161 (2): 429–45. doi:10.1016/j.jconrel.2011.11.028. PMID 22155554.
- ^ "Notification of Approval to Manufacture and Market Nanozora® 30mg Syringes for S.C. Injection, a Therapy for Rheumatoid Arthritis, in Japan Japan's First NANOBODY® Therapeutic" (Press release). Taisho Pharmaceutical Holdings. September 26, 2022.
Categories:
- Articles with short description
- Short description is different from Wikidata
- Drugs not assigned an ATC code
- Drugs with non-standard legal status
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Drugs that are a monoclonal antibody
- Drugs developed by Pfizer
- All stub articles
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs